Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development

Sarah Hargreaves*, Matthew Beasley, Chris Hurt, Terry M. Jones, Mererid Evans

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

12 Citations (Scopus)
45 Downloads (Pure)

Abstract

PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery (TOS) for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The study opened in the UK in October 2015 and, after successful recruitment into the phase II, transitioned into phase III in the autumn of 2018. PATHOS aims to establish whether the de-intensification of adjuvant treatment in patients with favorable prognosis HPV-positive OPSCC will confer improved swallowing outcomes, whilst maintaining high rates of cure. In this article, we will outline the rationale for the study and how it aims to answer fundamentally important questions about the safety, effectiveness and functional outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy (RT) or chemo-radiotherapy (CRT) in this patient population.

Original languageEnglish
Article number936
Number of pages9
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 1 Oct 2019

Keywords

  • adjuvant
  • deintensification
  • HPV-related head and neck squamous cell carcinoma
  • PATHOS
  • transoral surgery

Fingerprint

Dive into the research topics of 'Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development'. Together they form a unique fingerprint.

Cite this